Research shows how 'Mallard' dye fills need for speedFebruary 15, 2013
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood.
Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.
In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.
The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.
Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.
Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.
"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."
The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.
The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.
University of York
Related Heparin Current Events and Heparin News Articles
Anticoagulation medications show no gender-based variations in outcomes for TAVR patients
A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.
Snake venom could make surgery safer for patients on blood thinners
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung conditions, and for certain surgeries.
Snake venom helps hydrogels stop the bleeding
A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists.
Treatment for heparin-induced blood disorder revealed in structure of antibody complex
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
McMaster hematologist identifies different limb loss syndromes
How people can develop limb gangrene and lose fingers and feet has baffled doctors for centuries.
Lower risk treatment for blood clots 'empowers' patients, improves care
Potentially fatal blood clots account for thousands of emergency room visits each year and often those patients are admitted to the hospital, treated with an injectable anticoagulant and monitored for a few days.
Heart patients can stop blood thinners when undergoing elective surgery
Patients with atrial fibrillation who stopped taking blood thinners before they had elective surgery had no higher risk of developing blood clots and less risk of major bleeding compared to patients who were given a "bridge" therapy, according to research led by Duke Medicine.
Statewide quality improvement program helps lower rates of trauma complications
As health insurers place more emphasis on paying for quality outcomes rather than for specific services provided by doctors and hospitals, several quality improvement programs have been developed as a way to help health care providers identify problem areas and share best practices.
Low stent thrombosis rates with primary PCI, regardless of antithrombotic choice
Stent thrombosis following urgent angioplasty for acute heart attack occurred in less than 1% of patients in a large, "real-world" registry, regardless of whether the antithrombotic treatment used during the procedure was bivalirudin, heparin alone, or a GP IIb/IIIa inhibitor (typically in combination with heparin).
New studies examine the significant risk of blood clots in post-surgical lung cancer patients
One life-threatening complication of lung cancer surgery is the formation of blood clots in the lungs (also called pulmonary embolism - PE) or in the legs (also known as deep vein thrombosis - DVT).
More Heparin Current Events and Heparin News Articles